Iterum Therapeutics Limited is dedicated to developing significantly differentiated anti-infectives aimed at combatting MDR pathogens.
Employees: 11-50
Total raised: $157M
Founded date: 2015
Investors 7
Funding Rounds 3
| Date | Series | Amount | Investors |
| 17.01.2020 | - | $52M | - |
| 21.05.2017 | Series B | $65M | Arix Biosc... |
| 24.03.2016 | Series A | $40M | - |
Mentions in press and media 23
| Date | Title | Description |
| 06.03.2024 | Iterum Therapeutics Provides Business Update | - |
| 12.11.2021 | Iterum Therapeutics Reports Third Quarter 2021 Financial Results and Provides Business Update | --Type B meeting with FDA requested to affirm design for additional Phase 3 trial needed for resubmission of NDA for Oral Sulopenem-- --Cash Runway into 2024-- --Iterum to host conference call today at 8:30am ET-- DUBLIN, Ireland and CHICAG... |
| 30.09.2021 | Spero strikes $125M royalty deal for cUTI drug; French firm launches $100M early biotech fund | French investment firm Advent France Biotechnology (AFB) announced today the first closing of its second fund for a total of $102 million. Investors and participants in AFB’s fund included the European Investment Fund ... |
| 26.07.2021 | Eyeing quick approval, AbbVie offers a close-up on their presbyopia drug data | While everyone’s tuned into the Olympic Games in Japan, Cowen analysts put drugmakers through a pentathlon of their own — and in terms of R&D execution over the last 10 years, Denmark-based Novo Nordisk $NVO took home the gold. For the ... |
| 26.07.2021 | Small, struggling biotech winds up with a 3X loser as another PhIII of its lead drug collapses | Little Tonix Pharmaceuticals has run into another brick wall as its lead drug — a reformulated muscle relaxant originally approved 44 years ago — has failed another Phase III study, sending shares back into penny sto... |
| 26.07.2021 | FDA unsurprisingly brings down the hammer on Incyte's PD-1 — drawing a line for future accelerated approvals | It appears the PD-(L)1 honeymoon is finally over. Incyte $INCY revealed late Friday the FDA has slammed its PD-1 retifanlimab — which was under priority review for locally advanced or metastatic squamous cell carcino... |
| 26.07.2021 | Eyeing quick approval, AbbVie offers a close-up on their presbyopia drug data | AbbVie picked up some bonus points earlier this year as one of its pipeline adds from the $63 billion Allergan buyout hit its top-line marks. And now the researchers have produced the detailed data on the case they are making w... |
| 26.07.2021 | The clock is ticking for Iterum after FDA hands down CRL for Pfizer castoff antibiotic | Iterum knew its odds were slim as it awaited an FDA ruling on a key urinary tract infection drug with its bank account running low. The FDA, however, wasn’t impressed, and Iterum’s days look numbered. The FDA has sent the tiny bi... |
| 26.07.2021 | Eyeing quick approval, AbbVie offers a close-up on their presbyopia drug data | Denali Therapeutics had drummed up considerable hype for their blood-brain barrier technology since launching over six years ago, hype that’s only intensified in the last 14 months following the publications of a pair of papers last spring ... |
| 03.06.2020 | Iterum Therapeutics Announces $5 Million Registered Direct Offering Priced At-the-Market under Nasdaq Rules | - |
Show more